For Sprint Bioscience the third quarter was an intense and news-dense period. Thanks to a licensing agreement and a rights issue, the company now finds itself in its strongest financial position to date and ready to take the next step in its development. BioStock contacted CEO Erik Kinnman to get his view on the past quarter and on the future.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se